Use of hormone therapy for menopause is associated with reduced risks for esophageal, gastric, and colorectal cancers, according to results of a prospective study that were then combined with published studies in a meta-analysis. In this British study of women aged 50 to 64 years, researchers found no significant differences in risk by type of hormone therapy, duration of use, or between past and current users. The reduction in risk, however, was small in comparison to the increased risk of breast cancer that has been attributed to hormone therapy in this population.
Complete study results are available as an accepted manuscript on the website of the International Journal of Cancer (http://onlinelibrary.wiley.com.proxy.libraries.rutgers.edu/doi/10.1002/ijc.26236/abstract).